BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorino G, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Ungar B, Sebastian S, Furfaro F, Karmiris K, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris GJ, Armuzzi A, Boscà-watts MM, Ben-horin S, Bonovas S, Danese S. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology 2016;14:1426-1432.e1. [DOI: 10.1016/j.cgh.2016.05.044] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Chapman TP, Gomes CF, Louis E, Colombel J, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020;5:63-79. [DOI: 10.1016/s2468-1253(19)30186-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
2 Ungar B. Infliximab discontinuation in patients with ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:412-3. [PMID: 33887263 DOI: 10.1016/S2468-1253(21)00103-5] [Reference Citation Analysis]
3 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
4 Steinhart AH. Exit Strategies for Biologic Therapy in IBD: Is It Too Soon to Stop? Inflammatory Bowel Diseases 2018;24:669-70. [DOI: 10.1093/ibd/izx099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kobayashi T; HABYABUSA Study Group. Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply. Lancet Gastroenterol Hepatol 2021;6:688. [PMID: 34391518 DOI: 10.1016/S2468-1253(21)00253-3] [Reference Citation Analysis]
6 Petitcollin A, Brochard C, Siproudhis L, Tron C, Verdier M, Lemaitre F, Lucidarme C, Bouguen G, Bellissant É. Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases. Clin Pharmacol Ther 2019;106:605-15. [DOI: 10.1002/cpt.1429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
7 Kambayashi H, Omori T, Saito S, Murasugi S, Kashiwagi H, Ito A, Yonezawa M, Nakamura S, Tokushige K. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions. Intern Med 2020;59:2343-51. [PMID: 32999263 DOI: 10.2169/internalmedicine.5000-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
9 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
10 Frias Gomes C, Colombel JF, Torres J. De-escalation of Therapy in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20:35. [PMID: 29961926 DOI: 10.1007/s11894-018-0643-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)., Working panel., Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00137-2. [PMID: 35184989 DOI: 10.1016/j.dld.2022.01.127] [Reference Citation Analysis]
12 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
13 Jangi S, Holmer AK, Dulai PS, Boland BS, Collins AE, Pham L, Sandborn WJ, Singh S. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. J Crohns Colitis 2021;15:567-74. [PMID: 32914194 DOI: 10.1093/ecco-jcc/jjaa184] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Méndez-García LA, Trejo-Millán F, Martínez-Reyes CP, Manjarrez-Reyna AN, Esquivel-Velázquez M, Melendez-Mier G, Islas-Andrade S, Rojas-Bernabé A, Kzhyshkowska J, Escobedo G. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol 2018;88:e12716. [PMID: 30260514 DOI: 10.1111/sji.12716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
15 Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. Clin Ther 2017;39:849-862.e6. [PMID: 28363696 DOI: 10.1016/j.clinthera.2017.03.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
16 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mohamad HE, Asker ME, Keshawy MM, Abdel Aal SM, Mahmoud YK. Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway. Eur J Pharmacol 2020;872:172959. [PMID: 32004528 DOI: 10.1016/j.ejphar.2020.172959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Bots SJ, Kuin S, Ponsioen CY, Gecse KB, Duijvestein M, D'Haens GR, Löwenberg M. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scand J Gastroenterol 2019;54:281-8. [PMID: 30907185 DOI: 10.1080/00365521.2019.1582693] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Ben-horin S, Mao R, Qiu Y, Chen M. Discontinuation of Biological Treatments in Inflammatory Bowel Disease: A Concise Pragmatic Review. Journal of Clinical Gastroenterology 2018;52:6-12. [DOI: 10.1097/mcg.0000000000000938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
23 Wang L, Liu WZ, Pei LY, Ke YS, Cui J, Li SC. Garidisan: Improving the Quality of Ulcer Healing in Rats with Ulcerative Colitis. Evid Based Complement Alternat Med 2017;2017:8721257. [PMID: 28928792 DOI: 10.1155/2017/8721257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Scarallo L, Bolasco G, Barp J, Bianconi M, di Paola M, Di Toma M, Naldini S, Paci M, Renzo S, Labriola F, De Masi S, Alvisi P, Lionetti P. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis 2021:izab046. [PMID: 33835155 DOI: 10.1093/ibd/izab046] [Reference Citation Analysis]
25 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Louis E. Stopping Biologics in IBD-What Is the Evidence? Inflamm Bowel Dis. 2018;24:725-731. [PMID: 29548010 DOI: 10.1093/ibd/izx098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
28 Lee JM, Kim YJ, Lee KM, Yoon H, Lee BI, Kim DB, Kang D. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease. Scand J Gastroenterol 2018;53:1280-5. [PMID: 30351977 DOI: 10.1080/00365521.2018.1524024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang B, Gulati A, Alipour O, Shao L. Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis 2020;14:1413-23. [PMID: 32335670 DOI: 10.1093/ecco-jcc/jjaa087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Guillo L, Peyrin-Biroulet L, Louis E. Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story? J Crohns Colitis 2021;15:1087-8. [PMID: 33619541 DOI: 10.1093/ecco-jcc/jjab006] [Reference Citation Analysis]